A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results-Reference-Cited by-同舟云学术

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results

Published:2017-10-26 Issue:1 Volume:180 Page:41-51
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Spencer Andrew¹,Harrison Simon²³,Zonder Jeffrey⁴,Badros Ashraf⁵,Laubach Jacob⁶^ORCID,Bergin Krystal¹,Khot Amit²,Zimmerman Todd⁷,Chauhan Dharminder⁶,Levin Nancy⁸,MacLaren Ann⁸^ORCID,Reich Steven D.⁸,Trikha Mohit⁸,Richardson Paul⁶^ORCID

Affiliation:

1. Alfred Health-Monash University; Melbourne Australia

2. Peter MacCallum Cancer Centre; East Melbourne Australia

3. Melbourne University; Melbourne Australia

4. Karmanos Cancer Center; Detroit MI

5. University of Maryland Medical Center; Baltimore MD USA

6. Dana Farber Cancer Institute; Boston MA USA

7. Comprehensive Cancer Center; The University of Chicago Medicine; Chicago IL USA

8. Triphase Accelerator; San Diego CA USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14987/fullpdf

Reference41 articles.

1. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells;Altun;Cancer Research,2005

2. Cardiac complications in relapsed and refractory multiple myeloma receiving single agent carfilzomib;Atrash;Blood Cancer Journal,2015

3. Marizomib for CNS-multiple myeloma;Badros;British Journal of Haematology,2017

4. Investigation of pharmacodynamics and predictive biomarkers to define response to proteasome inhibitor marizomib in glioma. In Proceedings of the 107th Annual Meeting of the American Association of Cancer Research, 2016 Apr16-20, New Orleans, LA;Bota;Cancer Research,2016

5. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib;Chauhan;Cancer Cell,2005

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis;2024-05-17

2. TRAIL-induced apoptosis and proteasomal activity – Mechanisms, signalling and interplay;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-04

3. Development of Proteasome Inhibitors for Cancer Therapy;International Journal of Drug Discovery and Pharmacology;2024-03-18

4. Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies;Marine Drugs;2024-02-28

5. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors;Cell Communication and Signaling;2024-02-08